New hope for Alzheimer's pain: opioid combo trial launches
NCT ID NCT07323914
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial at Xuanwu Hospital in Beijing is testing whether a combination painkiller (oxycodone/acetaminophen) can safely ease chronic pain in 10 people with Alzheimer's disease. Participants will take the medication once daily for 12 weeks, with pain levels and side effects checked at several points. The goal is to find a better way to manage pain in patients who often cannot communicate their discomfort clearly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oxycodone/acetaminophen (Tylex)
What this could lead to
If successful, this could provide a safe and effective way to manage chronic pain in people with Alzheimer's disease, improving their comfort and quality of life.
What could go wrong
This is a very small trial with only 10 participants, so results may not apply to everyone. Opioids carry risks like drowsiness, falls, and dependence, especially in older adults with dementia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••